PROJECT TNBC

 Protein Inhibitors STAT3

 

 

 

 

Project co-financed by the European Union from the European Regional Development Fund under Measure 1.2: Sectoral R & D programs for the Intelligent Development Program 2014-2020. Contract No .: POIR.01.02.00-00-0036 / 15. Project co-funded by the National Center for Research and Development under the Innomed program.

 

Financing the project from the EU: 9 999 355,06 zł

STAT3 Inhibitors OF PROTEIN

GLG Pharma realizes the project pn. Development of targeted therapy for triple negative breast cancer (TNBC) based on innovative STAT-3 inhibitors such as GLG-805 or GLG-302 and the development of diagnostic tests based on immunochemical methods for rapid TNBC tumor diagnosis due to the presence of activated STAT- 3, as well as attempts to monitor protein concentrations in response to therapy with GLG-805 or GLG-302 molecules. " The TNBC project received in 2016 a grant from the INNOMED program, implemented by the National Research and Development Center under Measure 1.2: R & D Sectoral Operational Programs Intelligent Development 2014-2020 co-financed by the European Regional Development Fund. The value of the entire TNBC Project is PLN 13,586,612.76, of which PLN 9,999,355.07 will be financed by funds from the National Center for Research and Development, which accounts for approximately 74% of eligible costs. The project will be implemented in cooperation with subcontractors from leading Polish universities, research institutes and contract manufacturers.

 

The TNBC Project aims to develop a Triple Negative Breast Cancer (TNBC) targeted therapy based on the use of innovative GLG-805 or GLG-302 molecules.

 The TNBC Project is planned to:

  1. Development of appropriate non-toxic, unique GLG-805 or GLG-302 therapeutic formulations for oral or intravenous administration to ensure the stability of the pharmacologically active substance and high bioavailability in accordance with Good Manufacturing Practice (GMP) principles.
  2. Carry out pre-clinical testing on cell lines and animal models to confirm the safety and efficacy of GLG-805 or GLG-302-based therapy, as well as demonstrating the pharmacological effects of monotherapy as well as in combination with standard chemotherapeutics and other drugs. Used in anti-cancer therapy.
  3. Conduct clinical trials involving a group of patients with TNBC to assess safety and tolerability and maximum tolerated dose of the test product and effectiveness of therapy with new medicinal products.
  4. Development of a test for immunodiagnostics and monitoring of STAT-3 protein levels in patients with TNBC.

 

The research will be conducted on the basis of Good Clinical Practice (GCP) principles and based on European legal and regulatory standards and ethical principles. The new generation of therapies will be based on STAT-3 protein inhibitors, unique and small molecules that block the action of STAT-3 protein in cells, resulting in inhibition of uncontrolled growth of tumor cells. Therapy provides new treatment options with an alternative chemotherapy mechanism of action. The in vivo and in vitro studies in animal models have demonstrated the high efficiency of GLG Pharma molecules, by their ability to inhibit the growth of cancer cells, decrease tumors and prevent cancer.

In addition, STAT-3 inhibitors will also help to improve the effectiveness of chemotherapy and other targeted therapies by preventing and treating the acquired cancer cell resistance to oncological therapy. Commercialization of research results will take place in Poland. The results of industrial and development research will be widely disseminated through participation in national and international conferences and through publications in scientific journals.

 

We invite you to familiarize yourself with the inquiry request for the services provided under the project "Development of targeted therapy for triple negative breast cancer based on innovative STAT-3 protein inhibitors, ie GLG-805 or GLG-302, and development of diagnostic tests based on methods Immunochemistry for rapid TNBC tumor diagnosis due to the presence of activated STAT-3 protein, as well as attempts to monitor protein concentration in response to therapy with GLG-805 or GLG-302 molecules "under Action 1.2: Sectoral R & D programs for the Intelligent Development Program 2014 -2020 co-financed by the European Regional Development Fund

INQUIRIES

CONTACT

Contact Infomation

 

GLG Pharma S.A.

ul. Leszczyńskiego 4 lok. 25

50-078 Wrocław

Tel. (+48) 71 758 09 79

Fax. (+48) 71 750 35 50

Email: office@glgpharma.pl

Sending ...

Server error

Form received

GALLERY

 

 

PL

/

EN

Project by Marsa Design Studio

www.marsa.pl